Gram-negative bacteria

Recce Pharmaceuticals Announces Preclinical SARS-CoV-2 Study Update

Retrieved on: 
Tuesday, October 18, 2022
Degenerative disease, FSE, TCID50, ASX, Gram-negative bacteria, Virus, Infection, Animal, Severe acute respiratory syndrome coronavirus 2, Recce, Human, Pew, Hepatitis, Inhalation, HIV, Administration, Company, RCE, Intention, Patent, Safety, Bacteria, GLOBE, CSIRO, GAIN, Ferret, Real-time, FDA, COVID-19, Synthetic, CRO, Vaccine, Pharmaceutical industry

SYDNEY, Australia, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, is pleased to provide an update from its preclinical studies evaluating RECCE® 327 (R327) against the SARS-CoV-2 virus. The studies were conducted by Viroclinics, an independent, third-party contract research organization (CRO) based in the Netherlands.

Key Points: 
  • RECCE 327 (R327) was shown to significantly reduce SARS-CoV-2 levels in hamsters, the gold-standard in COVID-19 preclinical animal models
    New patents lodged supporting anti-infective capability in Brazil, Canada, China, Israel, India and Vietnam
    SYDNEY, Australia, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, is pleased to provide an update from its preclinical studies evaluating RECCE 327 (R327) against the SARS-CoV-2 virus.
  • The data received from Viroclinics indicates the potential of R327s capabilities as a treatment for viral infections," said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
  • Conducting our SARS-CoV-2 study in the Netherlands reaffirms the Companys intention to address the ongoing effects that Europe has experienced throughout the pandemic.
  • Considering the positive study results from the SARS-CoV-2 in-vivo hamster study at Viroclinics, the Company will consolidate its focus on anti-viral (COVID-19) studies overseas.

Indaptus Therapeutics to Present at the LD Micro Main Event XV

Retrieved on: 
Tuesday, October 18, 2022
U.S. Securities and Exchange Commission, Risk, SEC, Webcast, Therapy, Government, IND, Gram-negative bacteria, Neoplasm, Infection, Annual report, Spleen, Security (finance), Inflammation, Technology, Private Securities Litigation Reform Act, HIV, Immune system, Toxicity, Immunotherapy, Liver, HBV, Forward-looking statement, Immunology, Toxicology, Squamous cell carcinoma, Vaccine, Decoy

A replay of the webcast will be archived and available following the event for approximately 90 days.

Key Points: 
  • A replay of the webcast will be archived and available following the event for approximately 90 days.
  • Indaptus Therapeutics has evolved from more than a century of immunotherapy advances.
  • Indaptus patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, with reduced i.v.
  • toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity.

Peptilogics to Present Data at IDWeek 2022 on PLG0206, an Engineered Antimicrobial Peptide Targeting Bacteria Causing Periprosthetic Joint Infection

Retrieved on: 
Thursday, October 20, 2022
Biotechnology, Pharmaceutical, Surgery, General Health, Health, Medical Devices, Infectious Diseases, Clinical Trials, LinkedIn, United States Department of Health and Human Services, MIC, MRSA, Cystic Fibrosis Foundation, Biomedical Advanced Research and Development Authority, Founders Fund, Development, Klebsiella, Gram-negative bacteria, Debridement, Human services, Infection, QIDP, Cons, MSSA, Patient, Escherichia coli, Hospital, Research, Twitter, Staphylococcus aureus, Mortality, Inflammation, Enterobacter cloacae, Artificial intelligence, Technology, Solution, Staphylococcus, TKA, Cystic fibrosis, Administration, Department, Gram-positive bacteria, Klebsiella pneumoniae, Drug of last resort, Enterococcus, Enterobacter, Bacteria, MDR, Fast Track, Gram, S. aureus, Surgeon, Cancer, Algorithm, Pharmaceutical industry, Vaccine, Wellcome

Peptilogics, a clinical stage biotech company engineering peptide therapeutic solutions for patients with life-threatening diseases, is presenting two posters featuring preclinical data from its antimicrobial peptide, PLG0206, at IDWeek 2022 .

Key Points: 
  • Peptilogics, a clinical stage biotech company engineering peptide therapeutic solutions for patients with life-threatening diseases, is presenting two posters featuring preclinical data from its antimicrobial peptide, PLG0206, at IDWeek 2022 .
  • The studies demonstrate the potent activity of PLG0206 against bacteria that cause periprosthetic joint infections (PJI), including multidrug resistant (MDR) bacteria.
  • PJI is the most common complication of joint replacement surgery and is a life-changing event for patients.
  • MDR related infections pose a significant concern to patients as well as society in both the short- and long-term.

Venatorx Pharmaceuticals Presents Data on Investigational Cefepime-Taniborbactam at IDWeek 2022

Retrieved on: 
Thursday, October 20, 2022
General Health, Pharmaceutical, Health, Clinical Trials, National Institutes of Health, Degenerative disease, QIDP, Infection, Diarrhea, TOC, Genetically modified bacteria, Treatment, Test, Administration, National, Gram-positive bacteria, CEO, Bacteria, Pyelonephritis, MDR, United States Department of Health and Human Services, Urinary tract infection, Biomedical Advanced Research and Development Authority, Population, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Gram-negative bacteria, BARDA, Company, Department, Medication, CRE, FDA, AP, National Institute, Hypertension, Constipation, Nausea, Human services, LFU, Cefepime, Headache, Cutis marmorata, Wellcome Trust, New Drug Application, Patient, Food, BLI, Complicated, Adult, National Institute of Allergy and Infectious Diseases, Medical microbiology, Pseudomonas aeruginosa, Melioidosis, Pharmaceutical industry, Antibiotics, Safety, Meropenem

Venatorx Pharmaceuticals, a private, clinical-stage pharmaceutical company focused on improving health outcomes for patients with difficult-to-treat drug resistant gram-negative bacterial infections and viral infections, today will present new data during IDWeek 2022 for its novel investigational antibiotic cefepime-taniborbactam.

Key Points: 
  • Venatorx Pharmaceuticals, a private, clinical-stage pharmaceutical company focused on improving health outcomes for patients with difficult-to-treat drug resistant gram-negative bacterial infections and viral infections, today will present new data during IDWeek 2022 for its novel investigational antibiotic cefepime-taniborbactam.
  • The presentations, along with the four other posters detailing additional cefepime-taniborbactam data at IDWeek 2022 (see release ), will be available on the companys website.
  • We believe this data is meaningful given the sustained clinical benefit versus meropenem up to 3 to 4 weeks after treatment, said Christopher J. Burns, Ph.D. , President and CEO of Venatorx.
  • The safety data for cefepime-taniborbactam was consistent with the historical safety data for cefepime.

Venatorx Pharmaceuticals to Present at IDWeek 2022

Retrieved on: 
Tuesday, October 11, 2022
FDA, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, Degenerative disease, Urinary tract infection, New Drug Application, Infection, QIDP, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Gram-negative bacteria, Meropenem, Pyelonephritis, BARDA, Food, Company, Gram-positive bacteria, BLI, Adult, Safety, Tuberculosis verrucosa cutis, Bacteria, CRE, FDA, Pseudomonas aeruginosa, Melioidosis, Pharmaceutical industry, Cefepime

Cefepime-taniborbactam recently completed a Phase 3 study (CERTAIN-1) in adults with complicated urinary tract infections (cUTI), including pyelonephritis.

Key Points: 
  • Cefepime-taniborbactam recently completed a Phase 3 study (CERTAIN-1) in adults with complicated urinary tract infections (cUTI), including pyelonephritis.
  • In October 2022, BARDA awarded a contract of up to $318M for development and procurement of cefepime-taniborbactam for the treatment of melioidosis and multi-drug resistant infections.
  • Venatorx is a private, late-stage clinical pharmaceutical company focused on improving health outcomes for patients with multidrug-resistant bacterial infections and hard-to-treat viral infections.
  • In October 2022, BARDA awarded a contract of up to $318M for development and procurement of cefepime-taniborbactam for the treatment of melioidosis and multi-drug resistant infections.

Recce Pharmaceuticals Announces Expansion and Acceleration of Clinical Programs

Retrieved on: 
Monday, October 3, 2022
Urinary tract infection, FSE, Cystic fibrosis, GLOBE, Pyelonephritis, Recce, UTI, Infection, Urine, Streptococcus, Degenerative disease, RCE, Virus, Synthetic, FDA, ASX, GAIN, Gram-negative bacteria, Burn, Male, Mycobacterium abscessus, Bacteria, DFU, Sepsis, Safety, Streptococcus pneumoniae, Time-invariant system, Sydney, Pew, Patient, Kidney, Diabetic foot ulcer, Woman, Helicobacter pylori, Company, Pharmaceutical industry, Antibiotics, Vaccine

SYDNEY Australia, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) (the Company), the Company developing new classes of synthetic anti-infectives, is pleased to provide an updated timeline on its clinical programs with several significant data read-outs in 2022 and 2023.

Key Points: 
  • We have therefore established an ambitious development plan, aiming to get new anti-infective therapies into market as expediently possible.
  • Recces anti-infective pipeline is unique and comprised of broad-spectrum synthetic polymer antibiotics RECCE 327, RECCE 435, and RECCE 529 for viral infections with unique mechanisms of action against hyper-mutation on bacteria and viruses, respectively.
  • Recce wholly owns its automated manufacturing, ready to support first-in-human clinical trials.
  • Recces anti-infective pipeline seeks to exploit the unique capabilities of RECCE technologies targeting synergistic, unmet medical needs.

GSK and Spero Therapeutics Announce Exclusive License Agreement for Late-Stage Antibiotic Asset, Tebipenem HBr

Retrieved on: 
Thursday, September 22, 2022
Benchmark, Adult, Carbapenem, Meiji, Infection, Sinusitis, Biomedical Advanced Research and Development Authority, COVID-19, FDA, Food, Otitis media, Administration, Gram, U.S. Securities and Exchange Commission, Company, Genta (company), GSK, Access, Degenerative disease, AP, Therapy, Program, Patient, Cyprus Securities and Exchange Commission, Pneumonia, Technology, Pyelonephritis, Human services, QIDP, Tebipenem, Bacteria, Annual report, Hart–Scott–Rodino Antitrust Improvements Act, Urinary tract infection, Research, HBR, Marketing, Cutis marmorata telangiectatica congenita, Food and Drug Administration, Gram-negative bacteria, Disease, Pharmaceutical industry, Spero

LONDON and CAMBRIDGE, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- GSK (LSE/NYSE: GSK) and Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced they have entered into an exclusive license agreement for Spero’s late-stage antibiotic asset, tebipenem HBr. Tebipenem HBr is being developed as the first oral carbapenem antibiotic for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, caused by certain bacteria.

Key Points: 
  • In connection with the license agreement and pursuant to a stock purchase agreement between GSK and Spero, GSK has agreed to make a $9 million common stock investment in Spero, purchasing 7,450,000 shares of Speros common stock at a purchase price of approximately $1.20805 per share, not to exceed 19.99% beneficial ownership of Spero by GSK and its affiliates.
  • The closing of the equity investment is conditioned upon the effectiveness of the license following Hart-Scott-Rodino clearance.
  • As of June 30, 2022, Spero had cash, cash equivalents, and marketable securities of $45.4 million.
  • If approved, tebipenem HBr would be the first oral carbapenem antimicrobial to receive marketing approval in the United States.

ViaDerma Successfully Completes Quality Control Testing of its New Vitastem Products

Retrieved on: 
Thursday, September 15, 2022
Allergy, Time, Bacitracin, Gram-negative bacteria, OTC Markets Group, FDA, Psoriasis, Company, Acne, Burns, Dermatitis, OTC, CEO, Tetracycline, Bacteria, GLOBE, Skin, Pharmaceutical industry

LOS ANGELES, Sept. 15, 2022 (GLOBE NEWSWIRE) -- ViaDerma, Inc., (Company) (OTC Pink: VDRM) announces the successful completion of its internal quality control testing for their new Vitastem products.

Key Points: 
  • LOS ANGELES, Sept. 15, 2022 (GLOBE NEWSWIRE) -- ViaDerma, Inc., (Company) (OTC Pink: VDRM) announces the successful completion of its internal quality control testing for their new Vitastem products.
  • The Company implemented the testing as an additional precautionary safeguard since both products, Vitastem and Vitastem Ultra are using new formulations.The initial shipment of the new products has been received by ViaDerma allowing the Company to resume their online product sales.
  • The new and improved Vitastem and Vitastem Ultra are FDA-registered drugs and are among the strongest and most effective topical antibiotics available on the market.
  • Both Vitastem and Vitastem Ultra work similarly and provide the same great results.

National Institute of Health (NIH) awards InfeXtious Therapeutic a Small Business Technology Transfer (STTR) grant for the development of broad-spectrum cyclic amphiphilic peptides to combat antimicrobial resistance

Retrieved on: 
Thursday, September 8, 2022
Transfer, CA, CEO, National Institute, Small Business Innovation Research, Foundation for the National Institutes of Health, Agriculture, Death, STTR, Gram-negative bacteria, Centers for Disease Control and Prevention, NIH, Infection, Multimedia, Center, ULP, Aquaculture, Fungus, Chapman University, CDC, Antibiotics

IRVINE, Calif., Sept. 8, 2022 /PRNewswire/ -- InfeXtious Therapeutic announces a Small Business Technology Transfer (STTR) grant award from the National Institute of Health (NIH). In collaboration with Dr. Rakesh Tiwari of Chapman University, the grant will support the development of broad-spectrum cyclic amphiphilic peptides to combat antimicrobial resistance.

Key Points: 
  • IRVINE, Calif., Sept. 8, 2022 /PRNewswire/ -- InfeXtious Therapeutic announces a Small Business Technology Transfer (STTR) grant award from the National Institute of Health (NIH).
  • In collaboration with Dr. Rakesh Tiwari of Chapman University, the grant will support the development of broad-spectrum cyclic amphiphilic peptides to combat antimicrobial resistance.
  • The overuse of antibiotic drugs in agriculture, aquaculture, animal feed, and medicinehas led to the development of antibiotic-resistant bacteria.
  • InfeXtious Therapeutic is a small biotechnology company with a novel cyclic peptides platform to combat antimicrobial resistance.

Recce Pharmaceuticals Appoints Alistair McKeough to its Board of Directors

Retrieved on: 
Wednesday, September 7, 2022
Professional services, Risk management, Human, Gram-negative bacteria, Safety, Recce, Infection, Virus, Culture, Pakistan Library Automation Group, Pew, Board, FSE, Synthetic, GLOBE, McKeough, Leadership, Board of directors, Company, FDA, RCE, ASX, GAIN, Degenerative disease, Acquisition, Growth, Bacteria, Organic, Audit, Vaccine, Pharmaceutical industry

SYDNEY, Australia, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) (the Company) is pleased to announce the appointment of Alistair McKeough to its Board of Directors.

Key Points: 
  • SYDNEY, Australia, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) (the Company) is pleased to announce the appointment of Alistair McKeough to its Board of Directors.
  • The board and I are delighted to welcome Alistair as a non-executive director.
  • He knows the Company well, is excited about the future for Recce, and brings deep insights into Australias financial, corporate and regulatory environments.
  • On behalf of the board and shareholders, I welcome Alistair and Maggie and look forward to their contributions.